Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase I dose escalation trial with escalating doses of Valproic acid and one dose
escalation step of epirubicin. VPA will be escalated starting at a dose that is recommended
for use as an anti-convulsant or to treat migraine headaches. Epirubicin will be given by
infusion on day 3 after the last dose of divalproex. The study will determine the highest
dose that these two drugs can be given together and as part of a multidrug regimen with
5-fluorouracil and cyclophosphamide.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute